Arrowhead Research Corp. (Nasdaq: ARWR) began patient dosing in a Phase 2a clinical trial of ARC-520 to treat chronic hepatitis B but the stock price plummeted $3.33 to close at $17.37.
Arrowhead Research Plummets
March 24, 2014 at 18:55 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.